News Releases

Investor Alerts

Oct 25, 2019

IDEAYA Biosciences to Present at Upcoming Investor Conferences
Oct 8, 2019

IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor-Agnostic GNAQ/11 Basket Trial
Aug 12, 2019

IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
Jul 11, 2019

IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
Jul 9, 2019

IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone, J.D., as Chief Financial Officer, Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A, as Vice President, Development Operations
May 28, 2019

IDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
May 22, 2019

IDEAYA Announces Pricing of Initial Public Offering
May 8, 2019

IDEAYA Receives Authorization to Proceed with Phase 1/2 Tissue-Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ/11 Mutations and PKC Fusions
Mar 29, 2019

Updated Phase 1 Clinical Trial Monotherapy Data for IDE196 in Metastatic Uveal Melanoma to be Presented at AACR Conference
Feb 13, 2019

IDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick, Ph.D., FRS, and William Sellers, M.D., to Scientific Advisory Board

Show per page